Your browser doesn't support javascript.
loading
Prediction Model with HLA-A*33:03 Reveals Number of Days to Develop Liver Cancer from Blood Test.
Nishida, Nao; Ohashi, Jun; Suda, Goki; Chiyoda, Takehiro; Tamaki, Nobuharu; Tomiyama, Takahiro; Ogasawara, Sachiko; Sugiyama, Masaya; Kawai, Yosuke; Khor, Seik-Soon; Nagasaki, Masao; Fujimoto, Akihiro; Tsuchiura, Takayo; Ishikawa, Miyuki; Matsuda, Koichi; Yano, Hirohisa; Yoshizumi, Tomoharu; Izumi, Namiki; Hasegawa, Kiyoshi; Sakamoto, Naoya; Mizokami, Masashi; Tokunaga, Katsushi.
Afiliação
  • Nishida N; Genome Medical Science Project, National Center for Global Health and Medicine, Ichikawa 272-8516, Japan.
  • Ohashi J; Department of Genomic Function and Diversity, Medical Research Institute, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.
  • Suda G; Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo 113-0033, Japan.
  • Chiyoda T; Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo 060-8638, Japan.
  • Tamaki N; Hepato-Biliary-Pancreatic Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
  • Tomiyama T; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino 180-8610, Japan.
  • Ogasawara S; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
  • Sugiyama M; Department of Pathology, Kurume University School of Medicine, Kurume 830-0011, Japan.
  • Kawai Y; Department of Viral Pathogenesis and Controls, National Center for Global Health and Medicine, Ichikawa 272-8516, Japan.
  • Khor SS; Genome Medical Science Project-Toyama, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.
  • Nagasaki M; Genome Medical Science Project-Toyama, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.
  • Fujimoto A; Human Biosciences Unit for the Top Global Course Center for the Promotion of Interdisciplinary Education and Research, Kyoto University, Kyoto 606-8507, Japan.
  • Tsuchiura T; Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0003, Japan.
  • Ishikawa M; Genome Medical Science Project, National Center for Global Health and Medicine, Ichikawa 272-8516, Japan.
  • Matsuda K; Genome Medical Science Project, National Center for Global Health and Medicine, Ichikawa 272-8516, Japan.
  • Yano H; Laboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo 108-8639, Japan.
  • Yoshizumi T; Department of Pathology, Kurume University School of Medicine, Kurume 830-0011, Japan.
  • Izumi N; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
  • Hasegawa K; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino 180-8610, Japan.
  • Sakamoto N; Hepato-Biliary-Pancreatic Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
  • Mizokami M; Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo 060-8638, Japan.
  • Tokunaga K; Genome Medical Science Project, National Center for Global Health and Medicine, Ichikawa 272-8516, Japan.
Int J Mol Sci ; 24(5)2023 Mar 01.
Article em En | MEDLINE | ID: mdl-36902191
The development of liver cancer in patients with hepatitis B is a major problem, and several models have been reported to predict the development of liver cancer. However, no predictive model involving human genetic factors has been reported to date. For the items incorporated in the prediction model reported so far, we selected items that were significant in predicting liver carcinogenesis in Japanese patients with hepatitis B and constructed a prediction model of liver carcinogenesis by the Cox proportional hazard model with the addition of Human Leukocyte Antigen (HLA) genotypes. The model, which included four items-sex, age at the time of examination, alpha-fetoprotein level (log10AFP) and presence or absence of HLA-A*33:03-revealed an area under the receiver operating characteristic curve (AUROC) of 0.862 for HCC prediction within 1 year and an AUROC of 0.863 within 3 years. A 1000 repeated validation test resulted in a C-index of 0.75 or higher, or sensitivity of 0.70 or higher, indicating that this predictive model can distinguish those at high risk of developing liver cancer within a few years with high accuracy. The prediction model constructed in this study, which can distinguish between chronic hepatitis B patients who develop hepatocellular carcinoma (HCC) early and those who develop HCC late or not, is clinically meaningful.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article